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Abstract 
The commercialization of medical devices and biotechnology products is characterized 
by high failure rates and long development lead times particularly among start-up 
enterprises. To increase the success rate of these high-risk ventures, the University of 
Massachusetts Lowell (UML) and University of Massachusetts Medical School (UMMS) 
partnered to create key academic support centers with programs to accelerate 
entrepreneurship and innovation in this industry. In 2008, UML and UMMS founded the 
Massachusetts Medical Device Development Center (M2D2), which is a business and 
technology incubator that provides business planning, product prototyping, laboratory 
services, access to clinical testing, and ecosystem networking to medical device and 
biotech startup firms.  M2D2 has three physical locations that encompass approximately 
40,000 square feet. Recently, M2D2 leveraged these resources to expand into new 
areas such as health security, point of care technologies for heart, lung, blood, and 
sleep disorders, and rapid diagnostics to detect SARS-CoV-2. Since its inception, M2D2 
has vetted approximately 260 medical device and biotech start-up companies for 
inclusion in its programs and provided active support to more than 80 firms. This 
manuscript describes how two UMass campuses leveraged institutional, state, and 
Federal resources to create a thriving entrepreneurial environment for medical device 
and biotech companies. 
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Introduction 
The commercialization of innovative biomedical technologies is complex, time 
and resource intensive, and fraught with high failure rates. The University of 
Massachusetts Medical School (UMMS) and University of Massachusetts Lowell (UML) 
have a long-standing partnership to address these challenges and help innovators, 
especially start-up companies, commercialize their technologies. This manuscript 
describes the innovative programs that UMMS and UML have jointly developed as a 
guide to other academic institutions and companies wanting to design, expand and/or 
improve their entrepreneurial ecosystems.    
Biotechnology incubators are designed to help nurture new companies and limit 
costs related to capital equipment and administrative services. Incubators can operate 
as for-profit or not-for-profit; some take an equity stake in their resident companies and 
others do not. Incubators can also be grouped according to their affiliation (or lack of 
affiliation) with an academic center, local business development effort, or specific type 
of industry focus (1, 2). 
The Massachusetts Medical Device Development center (M2D2) is a technology 
and business incubator within the medical device and biotech industry.   Established in 
2008, the mission of M2D2 is to provide a lifeline for the state’s emerging medical 
device companies, offering inventors and executives easy, affordable, and coordinated 
access to world-class researchers and resources at the UML and UMMS campuses. 
These efforts help entrepreneurs bridge the product development ‘valley of death’ – that 
is the gap between academic research and commercial product launch (3, 4). M2D2 
combines the engineering and business expertise of UML faculty with the clinical 
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expertise of UMMS. Program staff has provided grant writing guidance, business 
development advice, and new company creation assistance. The center also forges 
connections to University faculty, students, and core research facilities. Access to 
physical incubator and office space, prototyping equipment, and clinicians for 
assistance with clinical studies are additional resources.   
Over the past 10 years, M2D2 has helped over 80 start-up companies advance 
the development of their medical devices and biotech innovations. There are currently 
43 companies that rent affordable laboratory space, close to but outside of the Kendall 
Square area of Boston (i.e., often referred to as the center of the nation’s biotechnology 
industry) and dozens more that are virtual tenants (i.e., they use M2D2 services but 
have a limited physical presence in the incubator). Due to the success of M2D2’s 
programs, 18 companies have graduated due either to acquisition or to the need to 
expand beyond the incubator space; only 6 companies have failed to date.  
Leadership and Governance 
Since M2D2 is a joint effort it draws from both institutions and leverages their 
complementary expertise.  It is organized as a center within the institutional structure of 
each campus. UML draws from its strong engineering, science and business tradition, 
while UMMS brings unparalleled medical expertise. M2D2 has a board of directors, an 
Executive Board, and an advisory board (Figure 1).  The board of directors is made up 
of leaders from each campus who provide overall leadership, guidance, and financial 
oversight of the center. The Executive Board meets once every two weeks.  At these 
meetings, the Executive Board discusses operational plans, evaluates the on-going 
progress of medical device and biotech entrepreneurs, and identifies target 
https://doi.org/10.1017/cts.2021.779
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 26 Apr 2021 at 15:27:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
organizations. Executive Board members come from both campuses and have 
expertise in nursing, technology transfer, engineering, business, clinical disciplines, 
health sciences, environmental health and safety, advancement, and media relations. 
The advisory board’s primary function is to assist with the evaluation of the innovative 
potential of early-stage ventures.   Advisory board members meet on a bi-annual basis 
to offer their assessment of target companies for investment.  This board is made up of 
senior executives from M2D2 sponsor companies such as Johnson and Johnson, 
Boston Scientific, and Amgen. Other business sponsors include representatives from 
the legal, prototyping, manufacturing, and regulatory industries. University sponsors, 
including the five-campus UMass Center for Clinical and Translational Science 
(UMCCTS), also sit on this board and provide significant institutional support. 
Prospective applicants are accepted into the M2D2 community through the 
following process. First, the interested company completes an application form and 
schedules a presentation at a bi-weekly Executive Board meeting. During the meeting 
the company presents a typical ‘business pitch deck’, describing the unmet need, the 
proposed solution, funds raised to date, intellectual property secured, the team and their 
expertise, and specific ways that the company plans to interact with the incubator. Next 
the Executive Board votes to accept or reject the applicant based on all these factors. 
Accepted companies complete a standard lease agreement and lab safety training 
before moving in. Over the past year occupancy rate across all three sites has averaged 
between 85-90%. Of the approximately 40 companies in residence in February 2021, 
10-15% are UMass spinouts, 30-35% are academic spinouts, and 20-25% were 
originally based out of state. Companies that are deemed too early to move in receive 
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individual feedback about their project and remain eligible to participate in all of our 
educational programming, office hours, networking, and competitions.  
Resources and Services 
M2D2 offers various business and technical services intended to increase the 
probability of early-stage success.  M2D2’s services broadly fall into one of the following 
categories: physical space; technical and engineering assistance; clinical and medical 
assessment, business development assistance; and networking and outreach (Table 1). 
Physical Space 
Physical space serves as an anchor for all these activities. In 2011, an initial 
investment of $4 million from the Massachusetts Life Sciences Center (MLSC), a state 
agency, supported the construction of the Wannalancit Mill space in Lowell. This 24,000 
square foot project created 6 private laboratories with shared office and conference 
space. In 2015, UML again partnered with MLSC to develop a second incubator site at 
110 Canal Street in Lowell. This $4 million project created 48 benches in an 11,000 sq ft 
open concept lab space along with shared office space, shared equipment, BSL2 
capabilities, and conference space. Most recently, M2D2 Worcester opened at the 
University of Massachusetts Medical School. This 1,500 sq ft space includes shared 
equipment, office, and conference room space along with 10 lab benches in an open-
concept laboratory environment. M2D2 has critical lab equipment to support early 
product development and importantly, as M2D2 increases capacity, it also increases 
economies of scale related to equipment purchase, use, and maintenance.  In the past 
year, over $150,000 has been invested in equipment and upgrades. Resident 
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companies are polled annually to see what kinds of shared equipment and resources 
are in demand, and M2D2 leadership acquires new instruments based on these 
responses. Access to common equipment within the M2D2 space is included as part of 
rent. Equipment and core resources that are not immediately contained within the lab 
space can be made available to companies  with proper training and regulatory 
approvals (5, 6).  Resident companies receive preferred rates at these cores and also 
qualify for a state-supported core resource voucher program (7, 8). Biosafety cabinets, 
environmental rooms, and other resources within the larger UMass environment are 
also available.   
Engagement 
As an incubator operated by a major research university, one of the most 
valuable services that M2D2 provides are connections to the UMass innovation 
ecosystem. The diverse representation of Executive Board, which includes leaders of 
the UMCCTS and campus technology transfer offices, facilities connections to people 
and resources across UMass. M2D2 staff frequently introduce companies to UMass 
faculty for clinical insights, engineering expertise, and business advice. M2D2 Executive 
Board members often make the initial introduction and additional connections are made 
according to the needs of the company. The vast majority of faculty are very willing to 
meet with these startups. Faculty have expressed interest in learning about emerging 
trends/technology and are motivated to help early-stage entrepreneurs. Interactions can 
be relatively brief and informal or develop into multi-year sponsored research programs.  
UMass students are another major resource for M2D2 companies.  In collaboration with 
the Massachusetts Life Sciences Center (MLSC) Internship Challenge (9), companies 
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gain access to students eager for real-world experience. At the end of the internship, 
the state MLSC program reimburses the company for the cost of the student’s stipend. 
Overall, M2D2 has placed over 120 students in our client companies and over 30 have 
developed into valued part- or full-time employees.   
Industry Partners 
Industry sponsors are an essential element of the entrepreneurial environment. 
In addition to providing financial support to M2D2 operations, sponsors support 
emerging companies through access to experienced entrepreneurs and large company 
expertise in deal-making, key technologies, product development, and 
commercialization. Some support comes in the form of educational programming 
through symposia and workshops. Programming is developed collaboratively between 
M2D2 leadership and industry sponsors based on feedback and survey responses from 
our membership. In 2020, M2D2 hosted 26 events with 1,870 attendees on topics 
including fund raising, mergers and acquisitions, intellectual property, and employment 
law. Additionally, 71 office hour sessions were held between sponsors and 387 resident 
attendees. Informal networking at events and through office hours are other ways new 
innovators learn valuable lessons about starting successful companies. Industry 
sponsors frequently remark that residents are highly motivated and responsive to input. 
These educational interactions often lead to long term business relationships that 
benefit both the mentor and mentee.   
Funding and Networking 
https://doi.org/10.1017/cts.2021.779
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 26 Apr 2021 at 15:27:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Annual pitch events are another way M2D2 partners with industry sponsors to 
provide startups the exposure and access to capital that is critical to bring technologies 
to market.  M2D2’s signature event is the “M2D2 $200K Challenge”, an annual 
competition designed to identify and reward up-and-coming companies in the medical 
device and biotechnology industries. Each year entrepreneurs are invited to pitch their 
technologies to a panel of experts selected from our industry sponsors. The competition 
has grown from 15 local applicants in 2012 to over 200 applicants from around the 
world in 2020. After an initial round of reviews conducted by the M2D2 Executive Board, 
selected finalists present their technology at a pitch and networking event to win a share 
of $200,000 of sponsor-provided, in-kind services. These services include laboratory 
space along with engineering, product development, legal, regulatory, clinical, and 
business services.  
Another pitch event is the “Barracuda Bowl”, a panel-style event modeled after a 
popular television show. Several entrepreneurs pitch their venture to a panel of 
investors and face questions regarding their technology, current stage of development, 
and financial projections.  Over the past six years, 40 different entrepreneurs have 
presented their technologies to 42 investors in front of over 800 attendees. 
These events have grown in popularity through a combination of factors: 
company word of mouth; advertising in trade publications and meetings; outreach via 
M2D2 sponsor and funding networks (see below); and partnerships with international 
business organizations. M2D2 works closely with the UMass tech transfer office on 
each campus to identify and nurture technologies that may be a good fit for the 
incubator. Members of the tech transfer office participate on the Executive Board. M2D2 
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does not take an equity stake in any company nor does it make any claim on IP 
developed in our facilities. 
Federally-supported Research Centers 
Over the first 10 years of its’ existence M2D2 developed through the hard work of 
the founding directors, board members, institutional champions on each campus 
including the UMCCTS, and significant support from state and internal resources. As 
the program has matured and demonstrated value to start-ups and established 
companies, several Federally-funded, peer reviewed centers have been established. 
CAPCaT 
In 2018, UMMS and UML received a 5-year, $7.9 million award from the National 
Institutes of Health (NIH) to establish the Center for Advancing Point of Care 
Technologies (CAPCaT) in heart, lung, blood, and sleep disorders. CAPCaT is one of 
five centers developing a pipeline of technologies with commercialization potential 
called the Point of Care Technology Research Network (POCTRN) (10). Innovations 
aim to help patients with these health concerns better manage their well-being wherever 
they are, seeking to reduce in-patient hospital stays and improve quality of life. While a 
major function of CAPCaT is to solicit and fund pilot projects, awardees are considered 
M2D2 resident companies and are therefore eligible to receive all the services and 
resources described above (Figure 2). In addition, these innovators receive added 
benefits such as participation in our annual innovator showcase, the Biotech East 
program, and the I-Corps short course.  
The innovator showcase event is designed to introduce our pilot grant awardees 
to potential large strategic investors and additional funding opportunities. Further, the 
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event is offered to the public to provide exposure to the awardees and to allow 
attendees, made up mainly of entrepreneurs, to learn directly from experts about best 
practices when seeking large strategic investments. Representatives from the NIH’s 
small business programs are also included to share information about funding 
opportunities and best practices for Small Business Innovation Research (SBIR) and 
Small Business Technology Transfer (STTR) applications. Our first event was held 
virtually in June 2020 due to the COVID-19 pandemic. Over 300 participants registered 
from 32 states and 7 countries. Sponsors included MPR Associates, Johnson & 
Johnson, Siemens Healthineers, Philips Ventures, Boston Scientific, Amgen Ventures, 
and NIH. 
The Biotech East program was founded in 2017 and is a joint collaboration 
between UML, the American Society of Cell Biology (ASCB) and Keck Graduate 
Institute (KGI) of the Claremont Colleges. The Biotech East program builds on the 
model developed in 2014 at KGI. The program offers a week-long, hands-on course to 
help U.S. and international advanced graduate students, PhD. students, and 
postdoctoral fellows transition to careers in biotech, medtech, or pharma (11). 
Programming teaches students the business side of science, professional development, 
networking skills, and interdisciplinary skills through MBA-style cases, keynote 
speakers, panels, and a team project. M2D2/CAPCaT is featured prominently in 
lectures, panels, and tours throughout the program, which draws students from top 
universities, such as the Massachusetts Institute of Technology, Harvard, Yale 
University, the University of Pennsylvania, and the University of Michigan. The program 
has gained an international reputation with students traveling from as far as Australia, 
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Brazil, Austria, Israel, and India to attend the program. Currently, nearly 70% of 
attendees that have attended the program have gone onto non-academic careers in 
industry, regulatory affairs, or tech transfer firms. 
The I-Corps short course program, a joint CAPCaT/UMass Center for Clinical 
and Translational Science (UMCCTS) initiative, is designed to support the 
commercialization of biomedical research by providing training in state of-the-art 
methods and strategic guidance to faculty, staff, and students during the early phases 
of technology development (12). The canonical I-Corps course offered by the NSF and 
NIH is intense, requiring 30+ hours of work per week for 7-8 weeks (13-15). Many 
small companies and academic inventors cannot afford that time commitment, 
especially in the early stages of development. CAPCaT leadership, along with 
colleagues at 8 other CTSA sites, are teaching an I-Corps short course curriculum 
specifically targeting medical product innovations, including point of care technologies. 
We plan to develop, evaluate, and disseminate a point of care technology module for 
the short course. The goal of this short course is to prepare participants to focus their 
R&D efforts beyond the laboratory, broaden the impact of their efforts, and enhance 
their capability to translate discoveries into commercially successful products that 
improve human health. A key element is to ensure that participants understand the 
patient care process – e.g., how innovations impact the current health care delivery 
model, how mobile devices create communication and POC monitoring opportunities, 
and how to distinguish product users from beneficiaries and purchasers.  The I-Corps 
program is offered annually for CAPCaT awardees, and all are expected to take this 
training as part of their award. Teams that achieve milestones and are chosen for 
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further development will be encouraged to attend the full NSF/NIH I-Corps program 
offered at the regional or national level. 
RADx 
In response to the COVID-19 pandemic the NIH established the Rapid 
Acceleration of Diagnostics (RADx) initiative to speed innovation in the development, 
commercialization, and implementation of technologies to detect SARS-CoV-2 nucleic 
acid and antigen, with the goal of making millions of tests per week available to 
Americans. RADx is a nationwide call for start-ups, established companies, and 
academic scientists to bring forth their novel, innovative ideas for new coronavirus 
testing methods. Those selected received funding and wrap-around services to move 
the approaches and strategies forward. As a member of POCTRN, UML and UMMS 
were selected by NIH leadership to play a key role in this effort. These activities were 
generally divided along the historical strengths of each campus. UML worked with 9 
RADx applicant companies to conduct preclinical stage experiments such as limit of 
detection studies, feasibility studies to achieve Emergency Use Authorization (EUA), 
system performance studies, cross-reactivity and analytical specificity studies, and to 
provide usability feedback.  Clinical research activities included a biorepository and 
studies of device usability, feasibility, and comfort. UMMS was selected to lead the 
clinical studies core - providing expertise in study design, management, data analysis, 
regulatory affairs, and logistics. Within two months of funding the clinical studies core 
opened their first study; within another four months the program had opened five multi-
site studies and enrolled over 1,000 participants. In all cases UMass resources were 
provided to innovators as an additional service to their RADx awards. We predict that 
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without these services, many small companies that participated in the RADx program 
would have had their project timelines delayed by the regulatory, preclinical, and 
clinical development process barriers that we identified and resolved.   
BARDA DRIVe 
The Biomedical Advanced Research and Development Authority (BARDA) is an 
office within the Department of Health and Human Services responsible for the 
procurement and development of medical countermeasures. M2D2 received a 5-year, 
$500,000 award from BARDA’s Division of Research, Innovation, and Ventures to scout 
innovative solutions looking to solve our nation’s greatest healthcare problems and aid 
in development process of more efficient medical countermeasures (16). 
M2D2 is one of thirteen incubators / accelerators that was chosen to be part of 
BARDA DRIVe’s National Accelerator Network. As the only New-England based 
accelerator program chosen for this initiative, M2D2 has been instrumental in 
connecting promising health security solutions from the Boston innovation ecosystem to 
crucial resources needed to advance their medical technology. In 2020, M2D2 hosted 
several programs such as: how to advance innovation in the health security space; how 
to get a startup technology into large hospital systems; and how to generate exposure 
for healthcare solutions looking to solve unmet clinical needs and improve health 
worldwide.  These programs reached over 750 people, showcased 9 promising 
innovations, and were seen in 14 countries. M2D2 has connected over 100 startups to 
BARDA’s resources, provided 7 companies with wrap-around support services, and 
facilitated over 11 market research calls with BARDA leadership. Areas of focus have 
included COVID-19, sepsis, bioterrorism, artificial intelligence, early notification of 
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diseases, and patient tracking and monitoring tools. M2D2 supports entrepreneurs in 
this space by providing our incubator resources, office hours, mentorship, and business 
development services to prospective and current BARDA DRIVe portfolio companies.  
Conclusions 
M2D2 has created a thriving entrepreneurial environment for medical device and 
biotechnology companies that want to commercialize their innovative products with 
support of a non-profit, academic partner. While early on M2D2 solely relied on support 
from the state, the UMass system, and industry partners, it has achieved a point of 
financial self-sufficiency and stability.  A key lesson was to focus on a specific sector- 
medical devices- early on and gradually expand into other sectors. M2D2’s metrics of 
success are similar to other incubators: number of startups in residence; number and 
trend of graduates, scale ups, and failures; new job creation; financial support and 
sponsorship from partners; and the number of UMass faculty and students engaged. 
M2D2’s success can be attributed to several factors: strong system and state support; 
diligent oversight and management of resources; dedicated faculty, staff, and partners; 
careful and deliberate growth; and committed external partners. As M2D2 and the rest 
of the world eagerly awaits the end of the COVID-19 pandemic, all involved continue to 
work diligently to ensure that innovation and entrepreneurship continue to thrive in this 
challenging environment. Currently, M2D2 is finalizing a strategic plan that was 
developed with internal and external stakeholders. This plan will incorporate emerging 
health trends that provide unprecedented opportunities for medical device and biotech 
developers in the coming years including remote monitoring, virtual medicine, and 
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digital health. This joint collaboration between UML and UMMS serves as a robust 
example of a high performing, university innovative ecosystem.   
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Figure 1. The Massachusetts Medical Device Development center (M2D2) is led by 
three different boards: a Board of Directors, an Executive Board, and an Advisory 
Board. 
  
Board  Board of Directors Executive Board Advisory Board Name  
M2D2 Organizational Structure and Key Roles 
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Type of Assistance Examples 
Physical space  Wet lab space 
 Core resources 
 Office and shared space 
Technical and engineering 
assessment 
 Materials selection 
 Product design and prototyping 
 Product manufacturing including injection 
molding, extrusion, blow molding, and material 
testing 
 Friction characterization, failure analysis, 
advanced materials characterization, and 
occupational biomechanics 
Clinical and medical 
assessment 
 Expert review and feedback in areas such as 
cardiology, orthopedics, surgery, diabetes 
 Access to patient populations 
 Regulatory support 
Business development  Business plan development 
 Feasibility and business scan development 
 Marketing plan development 
 Partner identification 
Networking and outreach  Educational programs 
 Mentoring 
 Pitch events and networking with banks, angel 
investors, venture capitalists, and industry 
partners 
Table 1. Massachusetts Medical Device Development center (M2D2) resources are 
grouped into five broad areas of support. Resident companies pay rent or membership 




















Figure 2. CAPCaT Resources. The Center for Advancing Point of Care Technologies 
(CAPCaT) in Heart, Lung, Blood, and Sleep Disorders  combines the expertise of the 
Massachusetts Medical Device Development center (M2D2) with National Institutes of 




Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 26 Apr 2021 at 15:27:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
References 
1. The Business Model of Biotechnology Incubators. Nature Biotechnology | Trade 
Secrets blog [Internet], May 13, 2011 [cited Mar. 15, 2021]. 
(http://blogs.nature.com/tradesecrets/2011/05/13/the-business-model-of-biotechnology-
incubators)  
2. Incubator vs Accelerator: What's the difference? University Lab Partners blog 
[Internet], 2019 [cited March 15, 2021]. 
(https://www.universitylabpartners.org/blog/incubator-vs-accelerator-whats-the-
difference) 
3. Massachusetts Medical Device Development Center and Biotech Incubator. 
[Internet], 2021 [cited Jan 29, 2021]. (https://www.uml.edu/research/m2d2/) 
4. Hafer N, McManus D, Picard M, et al.  M2D2: a successful model catalyzing 
medical device innovation and development.  Tech Connect Briefs. 2019 June; 409-
411.  ISBN: 978-0-9988782-8-7   
5. UMass Research Core Facilities. [Internet], 2021, [cited Jan 29, 2021]. 
(https://www.umassmed.edu/research/cores/) 
6. Core Research Facilities. [Internet], 2021, [cited Jan 29, 2021]. 
(https://www.uml.edu/research/crf/)  
7. UMass Core Facilities Voucher Program. [Internet], 2021, [cited Jan 29, 2021]. 
(https://www.umassmed.edu/research/voucher-program/) 
8. Massachusetts Innovation Voucher Program. [Internet], 2021, [cited Jan 29, 2021]. 
(https://www.uml.edu/research/crf/state-voucher-program.aspx). 
https://doi.org/10.1017/cts.2021.779
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 26 Apr 2021 at 15:27:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
9. Massachusetts Life Sciences Center Internship Challenge. [Internet], 2021, [cited Jan 
29, 2021]. (http://www.masslifesciences.com/programs/internship/) 
10. Point of Care Technology Research Network. [Internet], 2021, [cited Jan 29, 2021]. 
(https://www.poctrn.org/home) 
11. ASCB Biotech Courses. [Internet], 2021, [cited Jan 29, 2021], 
(https://www.ascb.org/career-development/biotech-course/) 
12. Nearing K, Rainwater J, Neves S, et al. I-Corps@NCATS trains clinical and 
translational science teams to accelerate translation of research innovations into 
practice. Journal of Clinical and Translational Science, 2020, Accepted manuscript , 
pp. 1 – 64, DOI: https://doi.org/10.1017/cts.2020.561 
13. We Have A Moral Obligation. [Internet], 2017, [cited Oct 24, 2017], 
(https://steveblank.com/category/nsf-national-science-foundation/)  
14. Osterwalder A, Pigneur Y. Business Model Generation. Hoboken, NJ: John Wiley 
& Sons; 2010. 
15. National Science Foundation. NSF Innovation Corps (I-Corps™). [Internet], 2021,  
[cited Jan 18, 2021], (https://www.nsf.gov/news/special_reports/i-corps/) 
16. DRIVe: Transforming Health Security. [Internet], 2021, [cited Jan 29, 2021] 
(https://www.drive.hhs.gov/) 
https://doi.org/10.1017/cts.2021.779
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 26 Apr 2021 at 15:27:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
